S&P 500

5.277,51

0,80%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Dicerna Pharmaceuticals Inc (DRNA)
Dicerna Pharmaceuticals Inc (DRNA) Notícias

DRNA

Dicerna Pharmaceuticals (DRNA)

Dicerna Pharmaceuticals Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:DRNA

1 2 3 4 5 6 7 8 9 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
14/02/2022	08:18	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
10/01/2022	19:00	Edgar (US Regulatory)	Termination of Registration of a Class of Security Under Section 12(b) (15-12b)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
03/01/2022	08:03	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
29/12/2021	18:23	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
28/12/2021	13:18	Edgar (US Regulatory)	Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
28/12/2021	13:15	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
28/12/2021	13:06	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
28/12/2021	12:52	Edgar (US Regulatory)	Amended Statement of Ownership: Solicitation (sc 14d9/a)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
28/12/2021	12:47	Edgar (US Regulatory)	Amended Tender Offer Statement by Third Party (sc To-t/a)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
28/12/2021	11:35	Edgar (US Regulatory)	Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
28/12/2021	11:29	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
28/12/2021	11:04	Business Wire	Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
25/12/2021	10:00	Business Wire	Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
09/12/2021	10:41	PR Newswire (US)	Direxion Launches mRNA ETF (MSGR)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
08/12/2021	20:55	TipRanks	Dicerna Pharma (DRNA) Gets a Hold Rating from Chardan Capital	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
25/11/2021	06:09	TipRanks	Leerink Partners Keeps a Buy Rating on Dicerna Pharma (DRNA)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
24/11/2021	19:07	Edgar (US Regulatory)	Statement of Ownership: Solicitation (sc 14d9)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
24/11/2021	18:58	Edgar (US Regulatory)	Tender Offer Statement by Third Party (sc To-t)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
19/11/2021	09:16	TipRanks	Dicerna Soars 78.7% on Novo Nordisk’s $3.3B Acquisition Offer	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
18/11/2021	19:32	Edgar (US Regulatory)	Written Communication Relating to an Issuer or Third Party (sc To-c)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
18/11/2021	19:08	Edgar (US Regulatory)	Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
18/11/2021	13:47	Dow Jones News	Dicerna Shares Soar on Takeover by Novo Nordisk	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
18/11/2021	09:51	Dow Jones News	Novo Nordisk to Buy Dicerna for $38.25 a Share	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
18/11/2021	09:00	Business Wire	Novo Nordisk to Acquire Dicerna	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
12/11/2021	10:54	Dow Jones News	Dicerna Pharma: Two Targets in Lilly Collaboration Meet Proof of Principle	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
12/11/2021	10:10	Business Wire	Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
12/11/2021	10:00	Business Wire	Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
09/11/2021	09:50	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
09/11/2021	09:30	Business Wire	Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc
04/11/2021	14:15	Business Wire	Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021	NASDAQ:DRNA	Dicerna Pharmaceuticals Inc